Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers.

Autor: Kong G; Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia., Noe G; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Chiang C; Department of Internal Medicine, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.; Department of Diabetes and Endocrinology, Melbourne Health, University of Melbourne, Parkville, Victoria, Australia., Herrmann K; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany., Hope TA; Department of Radiology, San Francisco VA Medical Center, San Francisco, California, USA.; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA., Michael M; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jazyk: angličtina
Zdroj: Journal of neuroendocrinology [J Neuroendocrinol] 2024 Nov 09, pp. e13461. Date of Electronic Publication: 2024 Nov 09.
DOI: 10.1111/jne.13461
Abstrakt: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine neoplasms (NEN). Its use is anticipated to increase significantly, and this demands accurate tools and paradigms to assess treatment response post PRRT. This article outlines the current role and future developments of anatomical, molecular imaging and biomarkers for response assessment to PRRT, highlighting the challenges and provides perspectives for the need to focus on a multimodality, multidisciplinary and individualised approach for patients with this complex heterogeneous disease.
(© 2024 The Author(s). Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.)
Databáze: MEDLINE
Externí odkaz: